



Clinical trial results:

A Phase 2 Trial of MLN0264 in Previously Treated Patients With Metastatic or Recurrent Adenocarcinoma of the Stomach or Gastroesophageal Junction Expressing Guanylyl Cyclase C (GCC) Summary

EudraCT number	2014-000804-88
Trial protocol	IT GB ES BE
Global end of trial date	15 January 2016

Results information

Result version number	v2 (current)
This version publication date	29 June 2017
First version publication date	31 January 2017
Version creation reason	<ul style="list-style-type: none">• Correction of full data set Updates based on QA comments from ClinicalTrials.gov.

Trial information

Trial identification

Sponsor protocol code	C26002
-----------------------	--------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02202759
WHO universal trial number (UTN)	U1111-1155-9023

Notes:

Sponsors

Sponsor organisation name	Millennium Pharmaceuticals, Inc.
Sponsor organisation address	40 Landsdowne Street, Cambridge, MA, United States, 02139
Public contact	Medical Director, Takeda, +1 877-825-3327,
Scientific contact	Medical Director, Takeda, +1 877-825-3327, trialdisclosures@takeda.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	15 January 2016
Is this the analysis of the primary completion data?	Yes
Primary completion date	15 January 2016
Global end of trial reached?	Yes
Global end of trial date	15 January 2016
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

The purpose of this study is to assess the efficacy, safety and tolerability of MLN0264 in patients with recurrent or metastatic guanylyl cyclase C (GCC)-positive adenocarcinoma of the stomach or gastroesophageal junction.

Protection of trial subjects:

All study participants were required to read and sign an Informed Consent Form

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	04 August 2014
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Belgium: 2
Country: Number of subjects enrolled	Spain: 10
Country: Number of subjects enrolled	United Kingdom: 4
Country: Number of subjects enrolled	United States: 22
Worldwide total number of subjects	38
EEA total number of subjects	16

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	15
From 65 to 84 years	23

85 years and over	0
-------------------	---

Subject disposition

Recruitment

Recruitment details:

Participants took part in the study at 24 investigative sites in Belgium, Spain, United Kingdom and the United States from 04 August 2014 to 15 January 2016.

Pre-assignment

Screening details:

Participants with a diagnosis of metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing Guanylyl Cyclase C (GCC) were enrolled in 1 treatment group, MLN0264 1.8 mg/kg, 30-minute IV infusion, Day 1 of each 21-day cycle.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	MLN0264 1.8 mg/kg (GCC Low)

Arm description:

MLN0264 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs (Up to 14 cycles). The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264. Participants with guanylyl cyclase C (GCC) protein expression=Low (combined H-score 10-59). Total H-score 0-600 is the combined score of cytoplasmic staining 0-300 and apical staining 0-300 and is based on the percentage of tumor cells with staining intensity 1+, 2+ and 3+.

Arm type	Experimental
Investigational medicinal product name	MLN0264
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for solution for injection/infusion
Routes of administration	Intramuscular and intravenous use

Dosage and administration details:

1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 of each 21-day cycle

Arm title	MLN0264 1.8 mg/kg (GCC Intermediate)
------------------	--------------------------------------

Arm description:

MLN0264 1.8 mg/kg, 30-minute IV infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs (Up to 9 cycles). The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264. Participants with guanylyl cyclase C (GCC) protein expression=Intermediate (combined H-score 60-119). Total H-score 0-600 is the combined score of cytoplasmic staining 0-300 and apical staining 0-300 and is based on the percentage of tumor cells with staining intensity 1+, 2+ and 3+.

Arm type	Experimental
Investigational medicinal product name	MLN0264
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for solution for injection/infusion
Routes of administration	Intramuscular and intravenous use

Dosage and administration details:

1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 of each 21-day cycle

Arm title	MLN0264 1.8 mg/kg (GCC High)
------------------	------------------------------

Arm description:

MLN0264 1.8 mg/kg, 30-minute IV infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs (Up to 8 cycles). The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264. Participants with guanylyl cyclase C (GCC) protein expression=Intermediate (combined H-score >120). Total H-score 0-600 is the combined score of cytoplasmic staining 0-300 and apical staining 0-300 and is based on the percentage of tumor cells with staining intensity 1+, 2+ and 3+.

Arm type	Experimental
Investigational medicinal product name	MLN0264
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for solution for injection/infusion
Routes of administration	Intramuscular and intravenous use

Dosage and administration details:

1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 of each 21-day cycle

Number of subjects in period 1	MLN0264 1.8 mg/kg (GCC Low)	MLN0264 1.8 mg/kg (GCC Intermediate)	MLN0264 1.8 mg/kg (GCC High)
Started	9	15	14
Completed	0	0	0
Not completed	9	15	14
Consent withdrawn by subject	2	1	1
Study Terminated by Sponsor	3	3	3
Reason not Specified	4	11	10

Baseline characteristics

Reporting groups

Reporting group title	MLN0264 1.8 mg/kg (GCC Low)
-----------------------	-----------------------------

Reporting group description:

MLN0264 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs (Up to 14 cycles). The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264. Participants with guanylyl cyclase C (GCC) protein expression=Low (combined H-score 10-59). Total H-score 0-600 is the combined score of cytoplasmic staining 0-300 and apical staining 0-300 and is based on the percentage of tumor cells with staining intensity 1+, 2+ and 3+.

Reporting group title	MLN0264 1.8 mg/kg (GCC Intermediate)
-----------------------	--------------------------------------

Reporting group description:

MLN0264 1.8 mg/kg, 30-minute IV infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs (Up to 9 cycles). The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264. Participants with guanylyl cyclase C (GCC) protein expression=Intermediate (combined H-score 60-119). Total H-score 0-600 is the combined score of cytoplasmic staining 0-300 and apical staining 0-300 and is based on the percentage of tumor cells with staining intensity 1+, 2+ and 3+.

Reporting group title	MLN0264 1.8 mg/kg (GCC High)
-----------------------	------------------------------

Reporting group description:

MLN0264 1.8 mg/kg, 30-minute IV infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs (Up to 8 cycles). The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264. Participants with guanylyl cyclase C (GCC) protein expression=Intermediate (combined H-score >120). Total H-score 0-600 is the combined score of cytoplasmic staining 0-300 and apical staining 0-300 and is based on the percentage of tumor cells with staining intensity 1+, 2+ and 3+.

Reporting group values	MLN0264 1.8 mg/kg (GCC Low)	MLN0264 1.8 mg/kg (GCC Intermediate)	MLN0264 1.8 mg/kg (GCC High)
Number of subjects	9	15	14
Age categorical			
Units: Subjects			
31 to 81 years	9	15	14
Age Continuous			
Units: years			
arithmetic mean	60.1	62.9	62.9
standard deviation	± 7.7	± 12.78	± 7.86
Gender, Male/Female			
Units: participants			
Female	1	5	1
Male	8	10	13
Height			
Units: cm			
arithmetic mean	169.7	167.8	171.1
standard deviation	± 7.49	± 9.85	± 9.38
Weight			
Units: kg			
arithmetic mean	71.51	71.67	72.75
standard deviation	± 11.25	± 17.06	± 12.59
Body Surface Area			

Units: m ²			
arithmetic mean	1.83	1.81	1.85
standard deviation	± 0.168	± 0.252	± 0.201

Reporting group values	Total		
Number of subjects	38		
Age categorical			
Units: Subjects			
31 to 81 years	38		
Age Continuous			
Units: years			
arithmetic mean	-		
standard deviation			
Gender, Male/Female			
Units: participants			
Female	7		
Male	31		
Height			
Units: cm			
arithmetic mean	-		
standard deviation			
Weight			
Units: kg			
arithmetic mean	-		
standard deviation			
Body Surface Area			
Units: m ²			
arithmetic mean	-		
standard deviation			

Subject analysis sets

Subject analysis set title	MLN0264 1.8 mg/kg
Subject analysis set type	Full analysis

Subject analysis set description:

MLN0264 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs (Up to 14 cycles). The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264.

Reporting group values	MLN0264 1.8 mg/kg		
Number of subjects	38		
Age categorical			
Units: Subjects			
31 to 81 years	38		
Age Continuous			
Units: years			
arithmetic mean	±		
standard deviation			

Gender, Male/Female Units: participants			
Female	7		
Male	31		
Height Units: cm arithmetic mean standard deviation	\pm		
Weight Units: kg arithmetic mean standard deviation	\pm		
Body Surface Area Units: m ² arithmetic mean standard deviation	\pm		

End points

End points reporting groups

Reporting group title	MLN0264 1.8 mg/kg (GCC Low)
-----------------------	-----------------------------

Reporting group description:

MLN0264 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs (Up to 14 cycles). The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264. Participants with guanylyl cyclase C (GCC) protein expression=Low (combined H-score 10-59). Total H-score 0-600 is the combined score of cytoplasmic staining 0-300 and apical staining 0-300 and is based on the percentage of tumor cells with staining intensity 1+, 2+ and 3+.

Reporting group title	MLN0264 1.8 mg/kg (GCC Intermediate)
-----------------------	--------------------------------------

Reporting group description:

MLN0264 1.8 mg/kg, 30-minute IV infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs (Up to 9 cycles). The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264. Participants with guanylyl cyclase C (GCC) protein expression=Intermediate (combined H-score 60-119). Total H-score 0-600 is the combined score of cytoplasmic staining 0-300 and apical staining 0-300 and is based on the percentage of tumor cells with staining intensity 1+, 2+ and 3+.

Reporting group title	MLN0264 1.8 mg/kg (GCC High)
-----------------------	------------------------------

Reporting group description:

MLN0264 1.8 mg/kg, 30-minute IV infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs (Up to 8 cycles). The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264. Participants with guanylyl cyclase C (GCC) protein expression=Intermediate (combined H-score >120). Total H-score 0-600 is the combined score of cytoplasmic staining 0-300 and apical staining 0-300 and is based on the percentage of tumor cells with staining intensity 1+, 2+ and 3+.

Subject analysis set title	MLN0264 1.8 mg/kg
Subject analysis set type	Full analysis

Subject analysis set description:

MLN0264 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs (Up to 14 cycles). The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264.

Primary: Overall Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors (RECIST)

End point title	Overall Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors (RECIST) ^[1]
-----------------	---

End point description:

ORR is defined as the percentage of participants with complete response (CR) or partial response (PR) as assessed by the investigator using Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. CR: Disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR: At least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions.

End point type	Primary
----------------	---------

End point timeframe:

Day 21, every other cycle, starting with Cycle 2 until disease progression, death or study closure (up to 17 months)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive statistics was planned for this endpoint.

End point values	MLN0264 1.8 mg/kg (GCC Low)	MLN0264 1.8 mg/kg (GCC Intermediate)	MLN0264 1.8 mg/kg (GCC High)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	9	14	13	
Units: percentage of participants	0	14	0	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

End point title	Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
-----------------	--

End point description:

An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) is defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/birth defect or is a medically important event. Relationship of each AE to study drug will be determined by the Investigator.

End point type	Secondary
----------------	-----------

End point timeframe:

From the first dose through 30 days after the last dose of study medication (Up to 10.7 months)

End point values	MLN0264 1.8 mg/kg (GCC Low)	MLN0264 1.8 mg/kg (GCC Intermediate)	MLN0264 1.8 mg/kg (GCC High)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	9	15	14	
Units: participants				
AEs	8	15	14	
SAEs	2	5	0	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Potentially Clinically Significant Laboratory Evaluation Findings

End point title	Number of Participants With Potentially Clinically Significant Laboratory Evaluation Findings
-----------------	---

End point description:

Participants with at least one post-baseline potentially clinically significant serum chemistry, hematology, coagulation or urinalysis result. Clinically significant results are those that were assessed by the investigator to be Grade 3 or higher using the National Cancer Institute Common Terminology

Criteria for Adverse Events (NCI CTCAE). Grade 3=severe, Grade 4=life threatening or disabling and Grade 5=Death.

End point type	Secondary
----------------	-----------

End point timeframe:

From the first dose through 30 days after the last dose of study medication (Up to 10.7 months)

End point values	MLN0264 1.8 mg/kg			
Subject group type	Subject analysis set			
Number of subjects analysed	38			
Units: participants				
Chemistry	8			
Hematology	13			
Coagulation	24			
Urinalysis	0			

Statistical analyses

No statistical analyses for this end point

Secondary: Progression Free Survival (PFS)

End point title	Progression Free Survival (PFS)
-----------------	---------------------------------

End point description:

PFS is defined as the time in days from the date of first study drug administration to the date of first documentation of disease progression or death. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

End point type	Secondary
----------------	-----------

End point timeframe:

Time Frame: Day 21 of every other 21-day cycle starting with Cycle 2, 30 days after the last dose of study medication, and then every 12 weeks for up to an additional 6 months (Up to 16.7 months)

End point values	MLN0264 1.8 mg/kg (GCC Low)	MLN0264 1.8 mg/kg (GCC Intermediate)	MLN0264 1.8 mg/kg (GCC High)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	9	14	13	
Units: days				
median (full range (min-max))	40 (38 to 311)	49 (38 to 316)	87 (39 to 427)	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Potentially Clinically Significant Vital Signs Findings

End point title	Number of Participants With Potentially Clinically Significant Vital Signs Findings
-----------------	---

End point description:

Participants with at least one potentially clinically significant post-baseline vital sign finding including measurements of diastolic and systolic blood pressure, heart rate, and oral temperature.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 of each 21 day cycle and 30 days after the last dose of study medication (Up to 10.7 months)

End point values	MLN0264 1.8 mg/kg			
Subject group type	Subject analysis set			
Number of subjects analysed	38			
Units: participants	0			

Statistical analyses

No statistical analyses for this end point

Secondary: Duration of Response

End point title	Duration of Response
-----------------	----------------------

End point description:

Duration of response is defined as the time in days from the date of first documentation of a confirmed response to the date of first documentation of disease progression. Per RECIST v1.1 for target lesions and assessed by magnetic resonance imaging (MRI) - CR: Disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR: At least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions.

End point type	Secondary
----------------	-----------

End point timeframe:

From first documented response until disease progression (Up to 16.7 months)

End point values	MLN0264 1.8 mg/kg			
Subject group type	Subject analysis set			
Number of subjects analysed	2 ^[2]			
Units: days				
median (full range (min-max))	45.5 (1 to 90)			

Notes:

[2] - Only two subjects had data collected due to early termination.

Statistical analyses

No statistical analyses for this end point

Secondary: Disease Control Rate

End point title	Disease Control Rate
-----------------	----------------------

End point description:

Disease control rate is defined as the percentage of participants with complete response (CR) or partial response (PR) or stable disease (SD) with a minimum of 12 weeks' duration. CR: Disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR: At least a 30% decrease in the sum of the Longest Diameter (LD) of target lesions, taking as reference the baseline sum LD and no new lesions. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) of target lesions, taking as reference the smallest sum LD since the treatment started and no new lesions. Investigator response is based on the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 21 of every other 21-day cycle starting with Cycle 2, 30 days after the last dose of study medication, and then every 12 weeks for up to an additional 6 months (Up to 16.7 months)

End point values	MLN0264 1.8 mg/kg (GCC Low)	MLN0264 1.8 mg/kg (GCC Intermediate)	MLN0264 1.8 mg/kg (GCC High)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	9	14	13	
Units: percentage of participants	11	36	54	

Statistical analyses

No statistical analyses for this end point

Secondary: Overall Survival (OS)

End point title	Overall Survival (OS)
-----------------	-----------------------

End point description:

Overall survival is defined as the time in days from the date of first study drug administration to the date of death.

End point type	Secondary
----------------	-----------

End point timeframe:

Until death or 6 months after the last patient completes treatment—whichever occurs first (Up to 17 months)

End point values	MLN0264 1.8 mg/kg (GCC Low)	MLN0264 1.8 mg/kg (GCC Intermediate)	MLN0264 1.8 mg/kg (GCC High)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	9	14	13	
Units: days				
median (full range (min-max))	230 (79 to 394)	156 (49 to 505)	206 (24 to 427)	

Statistical analyses

No statistical analyses for this end point

Secondary: Cmax: Maximum Observed Serum Concentration for MLN0264

End point title	Cmax: Maximum Observed Serum Concentration for MLN0264
-----------------	--

End point description:

Maximum observed serum concentration (Cmax) is the peak serum concentration of a drug after administration, obtained directly from the serum concentration-time curve.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycles 1-3 predose and 10 minutes, 4 hours, and 3, 4, 8 and 15 days postdose. Cycles 4+ predose, 10 minutes, 4 hours, and 4 and 8 days postdose.

End point values	MLN0264 1.8 mg/kg			
Subject group type	Subject analysis set			
Number of subjects analysed	0 ^[3]			
Units: µg/mL				
arithmetic mean (standard deviation)				

Notes:

[3] - No data was collected for this analysis due to early termination.

Statistical analyses

No statistical analyses for this end point

Secondary: MLN0264 Serum Concentrations

End point title	MLN0264 Serum Concentrations
-----------------	------------------------------

End point description:

Blood samples were collected and sent to a laboratory to be tested for serum concentrations of MLN0264.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycles 1-3 pre-dose and 10 minutes, 4 hours, and 3, 4, 8 and 15 days post-dose; Cycles 4-9 and 11-14 pre-dose and 10 minutes post-dose; End of Treatment.

End point values	MLN0264 1.8 mg/kg			
Subject group type	Subject analysis set			
Number of subjects analysed	38			
Units: µg/mL				
arithmetic mean (standard deviation)				
Cycle 1 Day 1, Pre-Dose (n=37)	0 (± 0)			
Cycle 1 Day 1, 10 Minutes Post-Dose (n=37)	37.0434 (± 9.93577)			
Cycle 1 Day 1, 4 Hours Post-Dose (n=38)	26.047 (± 6.27538)			
Cycle 1 Day 3, 48 Hours Post-Dose (n=35)	7.0839 (± 1.64899)			
Cycle 1 Day 4, 72 Hours Post-Dose (n=35)	4.4939 (± 1.25657)			
Cycle 1 Day 8, 168 Hours Post-Dose (n=38)	1.6795 (± 0.71586)			
Cycle 1 Day 15, 336 Hours Post-Dose (n=36)	0.5778 (± 0.22063)			
Cycle 2 Day 1, Pre-Dose (n=36)	0.7466 (± 2.68737)			
Cycle 2 Day 1, 10 Minutes Post-Dose (n=36)	32.1622 (± 9.61463)			
Cycle 2 Day 1, 4 Hours Post-Dose (n=36)	26.0278 (± 9.43156)			
Cycle 2 Day 3, 48 Hours Post-Dose (n=36)	7.7186 (± 2.04169)			
Cycle 2 Day 4, 72 Hours Post-Dose (n=33)	4.914 (± 1.05592)			
Cycle 2 Day 8, 168 Hours Post-Dose (n=35)	1.7813 (± 0.49456)			
Cycle 2 Day 15, 336 Hours Post-Dose (n=36)	0.6959 (± 0.27579)			
Cycle 3 Day 1, Pre-Dose (n=19)	0.4905 (± 0.77805)			
Cycle 3 Day 1, 10 Minutes Post-Dose (n=19)	31.1505 (± 8.74114)			
Cycle 3 Day 1, 4 Hours Post-Dose (n=19)	25.1787 (± 5.49543)			
Cycle 3 Day 3, 48 Hours Post-Dose (n=14)	6.736 (± 1.5694)			
Cycle 3 Day 4, 72 Hours Post-Dose (n=15)	5.887 (± 3.05461)			
Cycle 3 Day 8, 168 Hours Post-Dose (n=18)	1.5078 (± 0.48401)			
Cycle 3 Day 15, 336 Hours Post-Dose (n=18)	0.6807 (± 0.25869)			
Cycle 4 Day 1, Pre-Dose (n=16)	0.3916 (± 0.16462)			
Cycle 4 Day 1, 10 Minutes Post-Dose (n=15)	32.3427 (± 8.33045)			
Cycle 5 Day 1, Pre-Dose (n=7)	0.4757 (± 0.18995)			
Cycle 5 Day 1, 10 Minutes Post-Dose (n=7)	33.9286 (± 7.14793)			
Cycle 6 Day 1, Pre-Dose (n=8)	0.4915 (± 0.34173)			
Cycle 6 Day 1, 10 Minutes Post-Dose (n=8)	30.385 (± 7.79913)			
Cycle 6 Day 4, 72 Hours Post-Dose (n=7)	5.0676 (± 1.54862)			

Cycle 6 Day 8, 168 Hours Post-Dose (n=6)	1.691 (± 0.40781)			
Cycle 7 Day 1, Pre-Dose (n=3)	0.5097 (± 0.20409)			
Cycle 7 Day 1, 10 Minutes Post-Dose (n=3)	31.0133 (± 8.2343)			
Cycle 8 Day 1, Pre-Dose (n=3)	0.5677 (± 0.2418)			
Cycle 8 Day 1, 10 Minute Post-Dose (n=3)	31.6467 (± 8.93229)			
Cycle 9 Day 1, Pre-Dose (n=2)	0.929 (± 0.49639)			
Cycle 9 Day 1, 10 Minutes Post-Dose (n=2)	32.35 (± 6.77408)			
Cycle 11 Day 1, Pre-Dose (n=1)	0.776 (± 0)			
Cycle 11 Day 1, 10 Minutes Post-Dose (n=1)	56.84 (± 0)			
Cycle 12 Day 1, Pre-Dose (n=1)	0.735 (± 0)			
Cycle 12 Day 1, 10 Minutes Post-Dose (n=1)	49.88 (± 0)			
Cycle 13 Day 1, Pre-Dose (n=1)	0.887 (± 0)			
Cycle 13 Day 1, 10 Minutes Post-Dose (n=1)	41.64 (± 0)			
Cycle 14 Day 1, Pre-Dose (n=1)	1.026 (± 0)			
Cycle 14 Day 1, 10 Minutes Post-Dose (n=1)	41.92 (± 0)			
End of Treatment (n=26)	0.3323 (± 0.21216)			

Statistical analyses

No statistical analyses for this end point

Secondary: Serum Concentration of Total Antibodies (Conjugated and Unconjugated)

End point title	Serum Concentration of Total Antibodies (Conjugated and Unconjugated)
-----------------	---

End point description:

Blood samples were collected and sent to a laboratory to be tested for conjugated and unconjugated antibodies.

End point type	Secondary
----------------	-----------

End point timeframe:

Cycles 1-3 pre-dose and 10 minutes, 4 hours, and 3, 4, 8 and 15 days post-dose; Cycles 4-9 and 11-14 pre-dose and 10 minutes post-dose; End of Treatment.

End point values	MLN0264 1.8 mg/kg			
Subject group type	Subject analysis set			
Number of subjects analysed	38			
Units: µg/mL				
arithmetic mean (standard deviation)				
Cycle 1 Day 1, Pre-Dose (n=37)	0 (± 0)			

Cycle 1 Day 1, 10 Minutes Post-Dose (n=37)	41.8154 (\pm 10.05341)			
Cycle 1 Day 1, 4 Hours Post-Dose (n=38)	35.7626 (\pm 8.46954)			
Cycle 1 Day 3, 48 Hours Post-Dose (n=35)	16.0664 (\pm 3.26969)			
Cycle 1 Day 4, 72 Hours Post-Dose (n=35)	11.7461 (\pm 2.60098)			
Cycle 1 Day 8, 168 Hours Post-Dose (n=38)	6.1851 (\pm 1.73972)			
Cycle 1 Day 15, 336 Hours Post-Dose (n=36)	3.3926 (\pm 1.00149)			
Cycle 2 Day 1, Pre-Dose (n=36)	2.5995 (\pm 3.79916)			
Cycle 2 Day 1, 10 Minutes Post-Dose (n=35)	43.4749 (\pm 9.71796)			
Cycle 2 Day 1, 4 Hours Post-Dose (n=36)	35.6691 (\pm 10.26134)			
Cycle 2 Day 3, 48 Hours Post-Dose (n=36)	18.4167 (\pm 4.07769)			
Cycle 2 Day 4, 72 Hours Post-Dose (n=33)	13.3398 (\pm 3.23987)			
Cycle 2 Day 8, 168 Hours Post-Dose (n=35)	7.3613 (\pm 1.87974)			
Cycle 2 Day 15, 336 Hours Post-Dose (n=36)	4.3511 (\pm 1.47322)			
Cycle 3 Day 1, Pre-Dose (n=19)	2.5274 (\pm 1.54088)			
Cycle 3 Day 1, 10 Minutes Post-Dose (n=19)	41.3674 (\pm 11.88629)			
Cycle 3 Day 1, 4 Hours Post-Dose (n=19)	33.2692 (\pm 9.4253)			
Cycle 3 Day 3, 48 Hours Post-Dose (n=14)	15.95 (\pm 5.08026)			
Cycle 3 Day 4, 72 Hours Post-Dose (n=15)	12.8393 (\pm 4.56059)			
Cycle 3 Day 8, 168 Hours Post-Dose (n=18)	7.5035 (\pm 2.01984)			
Cycle 3 Day 15, 336 Hours Post-Dose (n=18)	4.2384 (\pm 1.66059)			
Cycle 4 Day 1, Pre-Dose (n=16)	2.9082 (\pm 1.03729)			
Cycle 4 Day 1, 10 Minutes Post-Dose (n=15)	45.4333 (\pm 13.8498)			
Cycle 5 Day 1, Pre-Dose (n=7)	3.2396 (\pm 0.88493)			
Cycle 5 Day 1, 10 Minutes Post-Dose (n=7)	43.0629 (\pm 7.30566)			
Cycle 6 Day 1, Pre-Dose (n=8)	3.081 (\pm 1.29133)			
Cycle 6 Day 1, 10 Minutes Post-Dose (n=8)	39.93 (\pm 10.13066)			
Cycle 6 Day 4, 72 Hours Post-Dose (n=7)	14.7957 (\pm 4.09897)			
Cycle 6 Day 8, 168 Hours Post-Dose (n=6)	9.6217 (\pm 1.53148)			
Cycle 7 Day 1, Pre-Dose (n=3)	3.3417 (\pm 1.64015)			
Cycle 7 Day 1, 10 Minutes Post-Dose (n=3)	42.1667 (\pm 8.725528)			
Cycle 8 Day 1, Pre-Dose (n=3)	3.0573 (\pm 1.21148)			

Cycle 8 Day 1, 10 Minute Post-Dose (n=3)	32.6333 (\pm 5.9498)			
Cycle 9 Day 1, Pre-Dose (n=2)	3.044 (\pm 0.98429)			
Cycle 9 Day 1, 10 Minutes Post-Dose (n=2)	45.8 (\pm 7.04278)			
Cycle 11 Day 1, Pre-Dose (n=1)	4.242 (\pm 0)			
Cycle 11 Day 1, 10 Minutes Post-Dose (n=1)	44.3 (\pm 0)			
Cycle 12 Day 1, Pre-Dose (n=1)	4.102 (\pm 0)			
Cycle 12 Day 1, 10 Minutes Post-Dose (n=1)	47.38 (\pm 0)			
Cycle 13 Day 1, Pre-Dose (n=1)	4.99 (\pm 0)			
Cycle 13 Day 1, 10 Minutes Post-Dose (n=1)	55.26 (\pm 0)			
Cycle 14 Day 1, Pre-Dose (n=1)	5.675 (\pm 0)			
Cycle 14 Day 1, 10 Minutes Post-Dose (n=1)	61.5 (\pm 0)			
End of Treatment (n=26)	2.5393 (\pm 1.32302)			

Statistical analyses

No statistical analyses for this end point

Secondary: Serum Concentration of Monomethyl Auristatin E (MMAE)

End point title	Serum Concentration of Monomethyl Auristatin E (MMAE)
End point description: Blood samples were collected and sent to a laboratory to be tested for MMAE.	
End point type	Secondary
End point timeframe: Cycles 1-3 pre-dose and 10 minutes, 4 hours, and 3, 4, 8 and 15 days post-dose; Cycles 4-9 and 11-14 pre-dose and 10 minutes post-dose; End of Treatment.	

End point values	MLN0264 1.8 mg/kg			
Subject group type	Subject analysis set			
Number of subjects analysed	38			
Units: ng/mL				
arithmetic mean (standard deviation)				
Cycle 1 Day 1, Pre-Dose (n=37)	0 (\pm 0)			
Cycle 1 Day 1, 10 Minutes Post-Dose (n=37)	0.473 (\pm 0.6503)			
Cycle 1 Day 1, 4 Hours Post-Dose (n=38)	2.659 (\pm 1.5489)			
Cycle 1 Day 3, 48 Hours Post-Dose (n=35)	6.153 (\pm 3.2773)			
Cycle 1 Day 4, 72 Hours Post-Dose (n=35)	5.856 (\pm 3.4519)			
Cycle 1 Day 8, 168 Hours Post-Dose (n=38)	2.945 (\pm 1.8899)			

Cycle 1 Day 15, 336 Hours Post-Dose (n=36)	0.532 (± 0.6693)			
Cycle 2 Day 1, Pre-Dose (n=36)	0.116 (± 0.1118)			
Cycle 2 Day 1, 10 Minutes Post-Dose (n=35)	0.425 (± 0.2697)			
Cycle 2 Day 1, 4 Hours Post-Dose (n=36)	2.665 (± 1.7137)			
Cycle 2 Day 3, 48 Hours Post-Dose (n=36)	6.746 (± 4.2361)			
Cycle 2 Day 4, 72 Hours Post-Dose (n=33)	6.111 (± 3.6283)			
Cycle 2 Day 8, 168 Hours Post-Dose (n=35)	2.898 (± 2.2974)			
Cycle 2 Day 15, 336 Hours Post-Dose (n=36)	0.579 (± 0.6221)			
Cycle 3 Day 1, Pre-Dose (n=19)	0.094 (± 0.124)			
Cycle 3 Day 1, 10 Minutes Post-Dose (n=18)	0.428 (± 0.4487)			
Cycle 3 Day 1, 4 Hours Post-Dose (n=19)	2.302 (± 1.8893)			
Cycle 3 Day 3, 48 Hours Post-Dose (n=14)	4.493 (± 2.6877)			
Cycle 3 Day 4, 72 Hours Post-Dose (n=15)	3.638 (± 1.857)			
Cycle 3 Day 8, 168 Hours Post-Dose (n=18)	2.135 (± 1.703)			
Cycle 3 Day 15, 336 Hours Post-Dose (n=17)	0.342 (± 0.3637)			
Cycle 4 Day 1, Pre-Dose (n=16)	0.081 (± 0.0865)			
Cycle 4 Day 1, 10 Minutes Post-Dose (n=15)	0.304 (± 0.1781)			
Cycle 5 Day 1, Pre-Dose (n=7)	0.084 (± 0.0331)			
Cycle 5 Day 1, 10 Minutes Post-Dose (n=7)	0.278 (± 0.1325)			
Cycle 6 Day 1, Pre-Dose (n=8)	0.093 (± 0.0654)			
Cycle 6 Day 1, 10 Minutes Post-Dose (n=7)	0.322 (± 0.2232)			
Cycle 6 Day 4, 72 Hours Post-Dose (n=7)	6.183 (± 3.3587)			
Cycle 6 Day 8, 168 Hours Post-Dose (n=6)	2.417 (± 1.6379)			
Cycle 7 Day 1, Pre-Dose (n=3)	0.044 (± 0.0083)			
Cycle 7 Day 1, 10 Minutes Post-Dose (n=3)	0.115 (± 0.0439)			
Cycle 8 Day 1, Pre-Dose (n=3)	0.058 (± 0.0103)			
Cycle 8 Day 1, 10 Minute Post-Dose (n=3)	0.132 (± 0.0425)			
Cycle 9 Day 1, Pre-Dose (n=2)	0.021 (± 0.0291)			
Cycle 9 Day 1, 10 Minutes Post-Dose (n=2)	0.158 (± 0.0721)			
Cycle 11 Day 1, Pre-Dose (n=1)	0.093 (± 0)			
Cycle 11 Day 1, 10 Minutes Post-Dose (n=1)	0.186 (± 0)			
Cycle 12 Day 1, Pre-Dose (n=1)	0.087 (± 0)			

Cycle 12 Day 1, 10 Minutes Post-Dose (n=1)	0.167 (± 0)			
Cycle 13 Day 1, Pre-Dose (n=1)	0.074 (± 0)			
Cycle 13 Day 1, 10 Minutes Post-Dose (n=1)	0.132 (± 0)			
Cycle 14 Day 1, Pre-Dose (n=1)	0.081 (± 0)			
Cycle 14 Day 1, 10 Minutes Post-Dose (n=1)	0.165 (± 0)			
End of Treatment (n=25)	0.173 (± 0.3359)			

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Reduction From Baseline in Tumor Size

End point title	Number of Participants With Reduction From Baseline in Tumor Size
End point description: The number of participants with the best percentage of tumor reduction from baseline in the sum of the diameter was calculated.	
End point type	Secondary
End point timeframe: Day 21 of every other 21-day cycle starting with Cycle 2, 30 days after the last dose of study medication, and then every 12 weeks for up to an additional 6 months (Up to 16.7 months)	

End point values	MLN0264 1.8 mg/kg (GCC Low)	MLN0264 1.8 mg/kg (GCC Intermediate)	MLN0264 1.8 mg/kg (GCC High)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	9	14	13	
Units: participants	1	2	4	

Statistical analyses

No statistical analyses for this end point

Secondary: Guanylyl Cyclase C (GCC) H-score Assessed by Immunohistochemistry (IHC)

End point title	Guanylyl Cyclase C (GCC) H-score Assessed by Immunohistochemistry (IHC)
End point description: Analysis of GCC protein expression levels in tumor tissue (fresh biopsy pretreatment and whenever a biopsy is considered medically safe and technically feasible) was performed using a semiquantitative immunohistochemistry (IHC) assay and the total GCC H-Score was determined. GCC H-score is based on the sum of the 0 to 300 H-score for cytoplasmic staining and the 0 to 300 H-score for apical staining for a total possible H-score 0 to 600. Separate consent was required to obtain archival tumor specimens for GCC expression assessment prior to screening.	
End point type	Secondary

End point timeframe:
Approximately 20 months

End point values	MLN0264 1.8 mg/kg (GCC Low)	MLN0264 1.8 mg/kg (GCC Intermediate)	MLN0264 1.8 mg/kg (GCC High)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	9	15	14	
Units: scores on a scale				
arithmetic mean (full range (min-max))	74.8 (27 to 100)	154.6 (110 to 230)	344.3 (260 to 480)	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Antitherapeutic Antibodies (ATA)

End point title	Number of Participants With Antitherapeutic Antibodies (ATA)
-----------------	--

End point description:

Blood samples were collected to assess the immunogenicity of MLN0264 (ATA development) using a laboratory test. Neutralizing ATA assessment was performed for ATA-positive samples only.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose of each 21 day cycle and 30 days after last dose of study medication (Up to 10.7 months)

End point values	MLN0264 1.8 mg/kg (GCC Low)	MLN0264 1.8 mg/kg (GCC Intermediate)	MLN0264 1.8 mg/kg (GCC High)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	9	15	14	
Units: participants	0	3	1	

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From the first dose through 30 days after the last dose of study drug (up to 10.7 Months)

Adverse event reporting additional description:

At each visit the investigator documented any occurrence of AEs and abnormal laboratory findings. Any event spontaneously reported by participant or observed by investigator was recorded, irrespective of relation to study treatment.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	18.0
--------------------	------

Reporting groups

Reporting group title	MLN0264 1.8 mg/kg
-----------------------	-------------------

Reporting group description:

MLN0264 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs (Up to 14 cycles). The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264.

Serious adverse events	MLN0264 1.8 mg/kg		
Total subjects affected by serious adverse events			
subjects affected / exposed	7 / 38 (18.42%)		
number of deaths (all causes)	1		
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Gastric cancer	Additional description: One treatment-emergent death occurred during treatment with MLN0264 with and is not related.		
subjects affected / exposed	1 / 38 (2.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Tumour hemorrhage			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Hip fracture			

subjects affected / exposed	1 / 38 (2.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Supraventricular tachycardia			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Dysphagia			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Upper gastrointestinal hemorrhage			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Bile duct obstruction			
subjects affected / exposed	1 / 38 (2.63%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	MLN0264 1.8 mg/kg		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	37 / 38 (97.37%)		
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	2 / 38 (5.26%)		
occurrences (all)	2		
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	10 / 38 (26.32%)		
occurrences (all)	16		
Fatigue			
subjects affected / exposed	12 / 38 (31.58%)		
occurrences (all)	14		
Pain			
subjects affected / exposed	2 / 38 (5.26%)		
occurrences (all)	2		
Oedema peripheral			
subjects affected / exposed	7 / 38 (18.42%)		
occurrences (all)	8		
Pyrexia			
subjects affected / exposed	4 / 38 (10.53%)		
occurrences (all)	5		
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	4 / 38 (10.53%)		
occurrences (all)	4		
Orthopnoea			
subjects affected / exposed	2 / 38 (5.26%)		
occurrences (all)	2		
Psychiatric disorders			
Depression			
subjects affected / exposed	2 / 38 (5.26%)		
occurrences (all)	2		
Confusional state			

subjects affected / exposed occurrences (all)	2 / 38 (5.26%) 2		
Investigations Blood alkaline phosphatase increased subjects affected / exposed occurrences (all) Gamma-glutamyltransferase increased subjects affected / exposed occurrences (all) Weight decreased subjects affected / exposed occurrences (all) Neutrophil count decreased subjects affected / exposed occurrences (all)	4 / 38 (10.53%) 4 4 / 38 (10.53%) 5 3 / 38 (7.89%) 4 4 / 38 (10.53%) 7		
Injury, poisoning and procedural complications Fall subjects affected / exposed occurrences (all)	2 / 38 (5.26%) 2		
Nervous system disorders Dizziness subjects affected / exposed occurrences (all) Tremor subjects affected / exposed occurrences (all) Neuropathy peripheral subjects affected / exposed occurrences (all) Hypoaesthesia subjects affected / exposed occurrences (all)	2 / 38 (5.26%) 2 2 / 38 (5.26%) 2 4 / 38 (10.53%) 6 2 / 38 (5.26%) 2		
Blood and lymphatic system disorders Neutropenia subjects affected / exposed occurrences (all)	5 / 38 (13.16%) 6		

Anaemia subjects affected / exposed occurrences (all)	6 / 38 (15.79%) 6		
Gastrointestinal disorders			
Abdominal pain subjects affected / exposed occurrences (all)	4 / 38 (10.53%) 5		
Constipation subjects affected / exposed occurrences (all)	9 / 38 (23.68%) 11		
Diarrhoea subjects affected / exposed occurrences (all)	6 / 38 (15.79%) 7		
Dysphagia subjects affected / exposed occurrences (all)	3 / 38 (7.89%) 3		
Ascites subjects affected / exposed occurrences (all)	2 / 38 (5.26%) 2		
Gastrooesophageal reflux disease subjects affected / exposed occurrences (all)	2 / 38 (5.26%) 2		
Nausea subjects affected / exposed occurrences (all)	20 / 38 (52.63%) 30		
Stomatitis subjects affected / exposed occurrences (all)	3 / 38 (7.89%) 5		
Vomiting subjects affected / exposed occurrences (all)	10 / 38 (26.32%) 13		
Skin and subcutaneous tissue disorders			
Alopecia subjects affected / exposed occurrences (all)	5 / 38 (13.16%) 6		
Renal and urinary disorders			

Proteinuria subjects affected / exposed occurrences (all)	2 / 38 (5.26%) 2		
Musculoskeletal and connective tissue disorders Back pain subjects affected / exposed occurrences (all) Musculoskeletal pain subjects affected / exposed occurrences (all) Myalgia subjects affected / exposed occurrences (all) Pain in extremity subjects affected / exposed occurrences (all)	4 / 38 (10.53%) 5 3 / 38 (7.89%) 3 2 / 38 (5.26%) 3 4 / 38 (10.53%) 4		
Infections and infestations Urinary tract infection subjects affected / exposed occurrences (all)	2 / 38 (5.26%) 2		
Metabolism and nutrition disorders Dehydration subjects affected / exposed occurrences (all) Decreased appetite subjects affected / exposed occurrences (all) Hypoalbuminaemia subjects affected / exposed occurrences (all) Hyperglycaemia subjects affected / exposed occurrences (all) Hypocalcaemia subjects affected / exposed occurrences (all)	3 / 38 (7.89%) 3 11 / 38 (28.95%) 13 4 / 38 (10.53%) 5 3 / 38 (7.89%) 4 4 / 38 (10.53%) 4		

Hypokalaemia			
subjects affected / exposed	2 / 38 (5.26%)		
occurrences (all)	2		
Hypomagnesaemia			
subjects affected / exposed	2 / 38 (5.26%)		
occurrences (all)	2		
Hyponatraemia			
subjects affected / exposed	2 / 38 (5.26%)		
occurrences (all)	3		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
31 March 2014	Amendment 1: The purpose of this amendment was to provide clarification and ensure consistency in the Schedule of Events.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported